North China Pharmaceutical Company Ltd.
Shanghai Stock ExchangeTotal Valuation
North China Pharmaceutical Company Ltd. carries a market capitalization of 7.96B, placing it among publicly traded companies globally. Its enterprise value stands at 20.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.96B |
| Enterprise Value | 20.43B |
Share Statistics
North China Pharmaceutical Company Ltd. currently has 1.72B shares outstanding.
| Shares Outstanding | 1.72B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
North China Pharmaceutical Company Ltd. trades at a trailing price-to-earnings ratio of 72.91. The price-to-sales ratio is 1.39, and the price-to-book ratio stands at 6.82.
| PE Ratio | 72.91 |
| PS Ratio | 1.39 |
| PB Ratio | 6.82 |
| P/TBV Ratio | 4.91 |
| P/FCF Ratio | 22.98 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, North China Pharmaceutical Company Ltd. trades at an EV/EBITDA multiple of 40.85 and an EV/FCF ratio of 34.91. The EV/Sales ratio of 3.09 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 40.85 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.09 |
| EV / EBITDA | 40.85 |
| EV / EBIT | 40.85 |
| EV / FCF | 34.91 |
Financial Position
North China Pharmaceutical Company Ltd. maintains a current ratio of 0.72, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 162.06, indicating elevated leverage, while an interest coverage ratio of 1.97 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.72 |
| Quick Ratio | 0.12 |
| Debt / Equity | 162.06 |
| Debt / EBITDA | 22.47 |
| Interest Coverage | 1.97 |
Financial Efficiency
North China Pharmaceutical Company Ltd. posts a return on equity of 9.73 and a return on invested capital of 1.99.
| Return on Equity (ROE) | 9.73 |
| Return on Assets (ROA) | 0.58 |
| Return on Invested Capital (ROIC) | 1.99 |
| Return on Capital Employed (ROCE) | 1.82 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.87 |
Taxes
Over the trailing twelve months, North China Pharmaceutical Company Ltd. has paid 66.41M in income taxes, reflecting an effective tax rate of 26.85.
| Income Tax | 66.41M |
| Effective Tax Rate | 26.85 |
Stock Price Statistics
North China Pharmaceutical Company Ltd.'s stock has declined approximately -27.38654% over the past 52 weeks. The 50-day moving average sits at 4.73, while the 200-day moving average is 5.47.
| Beta (5Y) | N/A |
| 52-Week Price Change | -27.38654% |
| 50-Day Moving Average | 4.73 |
| 200-Day Moving Average | 5.47 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, North China Pharmaceutical Company Ltd. generated 6.61B in revenue and converted that into 126.03M in net income, yielding earnings per share of 0.11. EBITDA reached 500.02M, while operating income came in at 500.02M.
| Revenue | 6.61B |
| Gross Profit | 2.10B |
| Operating Income | 500.02M |
| Pretax Income | 247.36M |
| Net Income | 126.03M |
| EBITDA | 500.02M |
| EBIT | 500.02M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
North China Pharmaceutical Company Ltd. holds 1.38B in cash and equivalents against 11.24B in total debt, resulting in a net debt position of 7.83B. Total book value stands at 1.35B, with working capital of -3.17B providing operational flexibility.
| Cash & Cash Equivalents | 1.38B |
| Total Debt | 11.24B |
| Net Debt | 7.83B |
| Equity (Book Value) | 1.35B |
| Book Value Per Share | 0.80 |
| Working Capital | -3.17B |
Cash Flow
After subtracting -399.84M in capital expenditures, free cash flow totaled -399.84M - equivalent to -0.24 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -399.84M |
| Free Cash Flow | -399.84M |
| FCF Per Share | -0.24 |
Margins
North China Pharmaceutical Company Ltd. operates with a gross margin of 31.83, reflecting its pricing power and cost economics. The operating margin of 7.56 and net profit margin of 1.91 provide insight into operational efficiency.
| Gross Margin | 31.83 |
| Operating Margin | 7.56 |
| Pretax Margin | 3.74 |
| Profit Margin | 1.91 |
| EBITDA Margin | 7.56 |
Dividends & Yields
The company's payout ratio of 119.27 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.17 |
| Dividend Yield | N/A |
| Payout Ratio | 119.27 |
| Shareholder Yield | 12.15 |
| FCF Yield | 4.35 |
Stock Splits
North China Pharmaceutical Company Ltd.'s most recent stock split took place on August 15, 2006 with a 125:196 split ratio.
| Last Split Date | 8/15/2006 |
| Split Ratio | 125:196 |
Scores
North China Pharmaceutical Company Ltd. posts an Altman Z-Score of 0.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.62 |